


26th Annual Report 2010-2011



Brawn Biotech Limited

(Formerly Brawn Pharmaceuticals Limited)
New Delhi



26th Annual General Meeting

Date 30th September, 2011

Day Friday.

Time 4.00 P.M.

Place "The Executive Club"

439, Vill-Shahoorpur, P.O. – Fatehpur Beri New Delhi – 110074

Contents

	Page No.
1.	Notice2
2.	Directors' Report4
3.	Management Discussion & Analysis 8
4.	Report on Corporate Governance 8
5.	Compliance Certificate on Corporate Governance 14
6.	Auditors' Report 15
7.	Balance Sheet 18
8.	Profit & Loss Account 19
9.	Schedules to the Accounts 20
10.	Cash Flow Statement 28
11.	Balance Sheet Abstract 29

BOARD OF DIRECTORS

Sh. B. R. Gupta Chairman-cum-

Managing Director

Smt. Urmila Gupta

Director

Smt. Brij Bala Gupta

Director

Sh. Manohar Lal

Director

Sh. Mahesh Kumar Nanchal

Director

Sh. Bal Kishan Sharma

Director

COMPANY SECRETARY

Sh. Amit Bansal

AUDITORS

M/s Satinder Saini & Co. Chartered Accountants

514, Suneja Tower – 1, District Center Janak Puri

New Delhi- 110058

BANKERS

Punjab National Bank H-22, Tropical Building, Connaught Place, New Delhi- 110001

REGISTERED OFFICE

C-64, Lajpat Nagar-I, New Delhi – 110024

CORPORATE OFFICE

4/4B, Asaf Ali Road, Old Delhi Stock Exchange Building, New Delhi – 110002

REGISTRARAND TRANSFERAGENT

FOR BOTH PHYSICAL& DEMAT M/s RCMC Share Registry Private Ltd., B-106, Sector – 2, Noida – 201301 (U.P.)

NOTICE

Notice is hereby given that the 26th Annual General Meeting of the Members of Brawn Biotech Limited (Formerly Brawn Pharmaceuticals Limited) will be held on Friday, the 30th September, 2011at 04:00 P.M. at "The Executive Club", 439, Vill. Shahoorpur, P.O. - Fatehpur Beri, New Delhi-110074 to transact the following businesses:

Ordinary Business:

- 1. To receive, consider and adopt the Audited Balance Sheet as at 31st March, 2011 and Profit and Loss Account for the year ended on that date and the Report of the Board of Directors' and Auditors' thereon.
- To appoint a Director in place of Mr. Manohar Lai, who retires by rotation and being eligible, offers himself for re-appointment.
- 3. To appoint a Director in place of Mr. Bal Kishan Sharma, who retires by rotation and being eligible, offers himself for re-appointment.
- 4. To reappoint Statutory Auditors' of the company and fix their remuneration and for the purpose to consider and if thought fit, to pass with or without modification, the following resolution as an ordinary resolution.

"RESOLVED THAT M/s Satinder Saini & Co., Chartered Accountants, 514, Suneja Tower - 1, District centre, Janak Puri, New Delhi - 110058 be and are hereby reappointed as statutory auditors of the company to hold office from the conclusion of ensuing Annual General Meeting until the conclusion of the next Annual General Meeting at a remuneration to be fixed by the Board of Directors of the Company."

Place: New Delhi Date: 03-09-2011 For and on behalf of the Board of Directors

Sd/-S.P. Gunta

(B.R. Gupta)

Chairman-Cum-Managing Director



Notes:

- a.) A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF AND SUCH PROXY NEED NOT BE A MEMBER OF THE COMPANY, A BLANK FORM OF PROXY IS ENCLOSED HEREWITH AND IF INTENDED TO BE USED, IT SHOULD BE RETURNED, DULY FILLED IN, TO THE REGISTERED/CORPORATE OFFICE OF THE COMPANY NOT LESS THAN FOURTY EIGHT HOURS BEFORE THE SCHEDULED TIME OF THE MEETING.
- b.) The Register of Members and Share Transfer Book of the Company will remain closed from Saturday, the 24th September, 2011 to Friday, the 30th September, 2011 (both days inclusive).
- c.) Shareholders are requested to intimate the change of address, if any, to the Company's Registrar & Transfer Agent M/s. RCMC Share Registry Private Limited, B-106, Sector-2, Noida 201301 (U.P.)
- d.) Members /Proxies should bring the attendance slip enclosed herewith duly filled in for attending the meeting. Members, who hold shares in dematerialized form are requested to bring their Client ID and DP ID Number for easy identification of attending at the meeting.
- e.) Shareholders seeking any information or having any query with regard to accounts are requested to write to the Company at least seven days before the date of the meeting, so as to enable the management to keep the information ready.
- f.) Members are requested to bring their copies of Annual Reports with them to the meeting, as extra copies of the Annual Reports will not be available for distribution at the meeting.

Place

: New Delhi

Date : 03-09-2011

For and on behalf of the Board of Directors

Sd/-

(B.R. Gupta)

Chairman-Cum-Managing Director

DIRECTORS' REPORT

Dear Shareholders.

The Directors of your Company have pleasure in presenting to you the Twenty Sixth Annual Report on the business & operations of the company and Audited Statement of Accounts for the year ended 31st March, 2011 along with the Auditor's Report thereon.

FINANCIAL RESULTS

The Financial Results of the Company for the year ended 31st March 2011 are as follows:

(Rs. in Lakh) **Particulars** Year ended Year ended 31.03.2011 31.03.2010 Gross Sales 1613.05 125.65 Profit before Depreciation & Interest 45.79 12.06 Interest 4 26 0.10 Depreciation 0.32 0.18 41.21 11.78 Profit/(Loss) before Tax Excess Provision for Income Tax of previous year written back 6.36 Provision for Gratuity 0.33 4 09 Provision for Leave Encashment 6.38 0.82 Provision for Income Tax 13.48 (37.22)Provision for Deferred Tax 21.35 48.18 Net Profit/(Loss) after Tax (117.39)(165.57)Profit/Loss brought forward Amount Available for Appropriation (96.04)(117.39)**Appropriations** Transfer to General Reserve (117.39)Balance carried to Balance Sheet (96.04)

OPERATIONS AND PERFORMANCE

During the year 2010-11, your Company's total sales and other income were Rs. 1613.05 Lacs and it earned profit of Rs. 41.21 Lacs in contrast to previous year's sales of Rs. 125.65 Lacs where it earned profits of Rs. 12.06 Lacs. It is apparent from the financials shown above that the sale of the Company has been increased by more than 1200 % and the net profit has also increased by more than 300 % in comparison with the previous year's results. As the performance of the company in the first two quarters of the current year is on the higher side, we are expecting better results in the future.

FUTURE PROSPECTS:

The Company is into aggressive marketing activities as a result of which the Company is showing better results from the past years. The Company has registered its products in international markets and has expanded its presence, as a result of which the export sale was of Rs. 70.87 Lacs during the year under report. Presently, the Company is also acting as consignee agent for the supplies to Government Hospitals and institutions. The Company is also planning to expand its business operations in the other states of territory of India, currently in which the company is not in operation.

DIVIDEND

Your Directors regret their inability to recommend any dividend for the year 2010-2011 to cover up the losses of the past years.



CHANGE OF NAME OF THE COMPANY

The name of the Company has been changed from Brawn Pharmaceuticals Limited to **Brawn Biotech Limited** w.e.f. 18.11.2010.

DIRECTORS

Mr. Manohar Lai and Mr. Bal Kishan Sharma retires by rotation and being eligible offers themselves for reappointment. Directors recommend their re-appointment.

AUDITORS

The Statutory Auditors, M/s Satinder Saini & Co., Chartered Accountants, New Delhi retires at the forthcoming Annual General Meeting and offers themselves for re-appointment as the Auditors' of the company.

As required under Section 224 (1B) of the Companies Act, 1956, the company has obtained from them a confirmation to the effect that their appointment, if made, would be in conformity with the limits prescribed in the said section.

AUDITORS' REPORT

Observations to the Auditors when read together with the relevant notes to the accounts and accounting policies are self-explanatory.

DEVELOPMENT

One of the main objectives of the company in the current financial year is to improve and develop good export market.

DIRECTORS' RESPONSIBILITY STATEMENT

The Board of Directors of your Company state:

- (a) That in the preparation of the Annual Accounts, the applicable accounting standards have been followed;
- (b) That the Directors had selected such accounting policies and applied them consistently and made judgment and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period:
- (c) That the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities:
- (d) That the Directors had prepared the annual accounts for the year ended 31st March 2011 on a going concern basis.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNING AND OUTGO

Particulars in respect of conservation of energy, technology absorption and other particulars required under Section 217 (1)(e) of The Companies Act, 1956 read with the Companies (Disclosure of Particulars in the report of the Board of Directors) Rules, 1988 is enclosed as Annexure 'A' and forms part of this report.

CORPORATE GOVERNANCE

Your Company believes in conducting the business with due compliance of all the applicable laws, rules and regulations. The Company has duly implemented the system of corporate governance as per the requirements of the Listing Agreement. Detail report appears in the Annexure forming part of this report.

EMPLOYEES RELATION

Your Directors wish to express their sincere appreciation of the efficient services rendered by the employees at all levels throughout the company.



PERTICULARS OF EMPLOYEES

None of the Employee of the Company has received remuneration above the limits as prescribed in Sub-section 2A of Section 217 of the Companies Act, 1956 read with Companies (Particular of Employees) Rules, 1975.

FIXED DEPOSIT

The Company has not accepted any fixed deposit from the public during the year under review.

ACKNOWLEDGEMENT

Your Directors wish to place on record their gratitude to the Government Authorities, Company's Bankers, Dealers, Customers and its Business Associates for their valued support extended to the company.

Place

: New Delhi

Date

: 03-09-2011

For and on behalf of the Board of Directors

Sd/-

(B.R. Gupta)

Chairman-Cum-Managing Director



ANNEXURE TO THE DIRECTORS' REPORT

STATEMENT OF PARTICULARS UNDER THE COMPANIES (DISCLOSURE OF PARTICULARS IN THE REPORT OF BOARD OF DIRECTORS) RULES, 1988

(A) Conservation of Energy

(i) Energy Conservation Measure taken

(ii) 1) Preventive maintenance of equipment

N.A.

to seal energy wastages.

2) Regular day to day monitoring of energy Consumption items.

N.A.

(iii) Total and per unit energy consumption

The figure-A(see Rule-A Form-A (see Rule-2)

Power and fuel consumption

N.A.

(B) Technology absorption

N.A.

(C) Expenditure on R&D

N.A.

(D) Foreign Exchange earnings

Rs. 70.87 Lac

(Rs. In Lacs)

		Year ended 31st March 2011	Year ended 31st March 2010
a)	Total foreign Exchange earned	70.87	58.72
b)	Total foreign Exchange used on Import of raw materials, spare parts and capital goods	-	-
c)	Expenditure in Foreign Currencies for travels, subscription, consumables stores, goods for resale, commission on export sales etc.	-	-
d)	Remittance during the year in foreign currency on account of dividend.	-	-

Place

: New Delhi

Date

: 03-09-2011

For and on behalf of the Board of Directors

Sd/-

(B.R. Gupta)

Chairman-Cum-Managing Director



MANAGEMENT DISCUSION AND ANALYSIS REPORT

OUTLOOK

The pharmaceutical industry is core to the Indian economy, a battle ground of major global majors in the pharmaceutical sectors. The industry is increasingly responding to the need to reduce various vulnerable diseases and enhance safety through vast development of life savings drugs and medicines. Its growth is being catalysed by a significant gap between demand and supply. As a result, with increasing competition, consumer preference will become paramount and product differentiation is expected to play a major role in success.

FINANCIAL AND OPERATIONAL PERFORMANCE

The same has been discussed in the Board of Directors' Report.

HUMAN RESOURCES

Adequate facilities and opportunities are also being provided to the staffs to update themselves in the fast changing era of technologies.

COMPANY PERFORMANCE

The company could not leverage its rich technological and marketing strengths to its full capacity during the period under review due to various constraints. Even in this challenging situation the Company strives to regain its lost vigour and vitality.

INTERNAL CONTROL & ADEQUACY

Your company has a proper and adequate system of internal control. Your company also ensures that transactions are authorized, recorded and reported correctly.

PROSPECTS

In the wake of the ongoing economic reforms, the company is expected to make a strong showing through its current emphasis on high value added jobs, which would require considerable reinforcement in the areas of pharmaceuticals and image building as a reliable supplier with quality assurance.

CAUTIONARY NOTE

The MD&A, detailing the Company's objectives, projections, estimates and expectations, may contain 'forward looking statements' within the meaning of applicable laws and regulations. These statements are based on certain assumptions and expectations of future events. The actual results may differ substantially or materially from those expressed or implied. The company assumes no responsibility to publicity amend, modify or revise any forward working statements, on the basis of any subsequent developments, information or events.

REPORT ON CORPORATE GOVERNANCE

The Company continues to implement the code of Corporate Governance during the year under reference in terms of clause 49 of the Listing Agreement with Stock Exchanges.

1. BRIEF NOTE ON COMPANY'S PHILOSOPHY

Corporate Governance primarily involves transparency, full disclosure, independent monitoring of the state of affairs and being fair to all stakeholders. A good Corporate Governance lead to long term shareholders value and enhances interest of other stakeholders. It brings in to focus the fiduciary and trusteeship role of the Board to align and direct the actions of the organization towards creating wealth and shareholder value.

The Company has always believed in good Corporate Governance and Standard Corporate Practice. The company has always remained prompt and regular in discharging its statutory obligations and duties.



Brawn Biotech Ltd.

The Board of Directors has constituted various committees such as Audit Committee, Remuneration Committee and Shareholders'/investors' Grievances Committee. The meetings of the Board and Committees thereof have been held as frequently as required for proper and effective control over the affairs of the Company. All the directors, attending the Board and Committee Meetings, actively participate in the proceedings.

2. BOARD OF DIRECTORS

The Board of Directors comprises one Chairman-cum-Managing Director, two Non Executive Promoter Director and three Non Executive Independent Directors.

During the year, 13 Board Meetings were held.

The particulars regarding composition of the Board of Directors, particulars of Directors, other directorship of other public limited Companies and their attendance in the Meetings held during the year under review are given hereunder:

Name of the Directors & Category of Directorship		Director public compan	ship in other limited ies	Committ Member Other pu Compan	ship held in ublic			Attende d Last AGM	No. of share held in the company
		Total	As Chairman	Total	Chairm an	Held	Attende d		
B.R. Gupta	Chairman & M.D	1	NIL	NIL	NIL	13	13	Yes	3,77,650
Brij Bala Gupta	Non-Executive Promoter Director	1	NIL	NIL	NIL	13	13	No	89,600
Urmila Gupta	Non-Executive Director	1	NIL	NIL	NIL	13	0	No	NIL
Manohar Lal	Non-Executive Independent Director	NIL	NIL	NIL	NIL	13	13	Yes	NIL
Mahesh Kumar Nanchal	Non-Executive Independent Director	NIL	NIL	NIL	NIL	13	13	Yes	3,100
Bal Kishan Sharma	Non-Executive Independent Director	NIL	NIL	NIL	NIL	13	13	Yes	NIL

1. COMMITTEE OF THE BOARD

The Board of Directors have constituted the following Committees with adequate delegation of powers.

A. Audit Committee

Composition of Audit Committee meets all the criteria as prescribed by law. The committee comprises of three Directors, who are Non Executive & Independent. It met four times during the year 2010-11 on 10th May, 2010; 12th August, 2010, 10th November, 2010 and 14th February, 2011.



The details of the meeting of Audit Committee attended by the members are as under:-

Members of Audit Committee	Category	Meetings held	Meetings attended
Mr. Manohar Lal	Chairman	4	4
Mr. Mahesh Kumar Nanchal	Member	4	4
Mr. Bal Kishan Sharma	Member	14	14

B. Share Transfer & Shareholders/Investors' Grievance Committee

The Share Transfer & Shareholders/Investors' Grievance Committee of the Company looks into the matters like transfer/transmission, issuance of duplicate shares, non-receipt of Annual Reports and declare dividend etc. and investigate the investor's complaints and take necessary steps for redressal thereof.

The details of the meeting of Share Transfer & Shareholders/Investors' Grievance Committee attended by the members are as under:-

Members	Category	Meetings held	Meetings attended
Mr. Manohar Lal	Chairman	20	20
Mr. Mahesh Kumar Nanchal	Member	20	20
Mr. Bal Kishan Sharma	Member	20	20

C. Remuneration Committee

Remuneration Committee of the Board of Directors recommends/reviews the remuneration package of Managing Director & Whole Time Directors. The Remuneration Committee comprises of following Directors.

Members	Category
Mr. Manohar Lal	Chairman
Mr. Mahesh Kumar Nanchal	Member
Mr. Bal Kishan Sharma	Member

1. General Body Meeting

(i) Location and time where last three AGMs were held:

Year	Date	Location	Time
2009-10	28 th September, 2010	Executive Club, 439, Vill -Shahoorpur, P.O., Fatehpur Beri, N.D-110074	9.30 a.m.
2008-09	26 th September, 2009	Executive Club, 439, Vill -Shahoorpur, P.O., Fatehpur Beri, N.D-110074	9.30 a.m.
2007-08	29 th September, 2008	Executive Club, 439, Vill -Shahoorpur, P.O., Fatehpur Beri, N.D-110074	9.30 a.m.

(ii) Special resolutions passed in the previous 3 AGMs:

28.09.2010: Special resolution for change of name of the Company from Brawn Pharmaceuticals Limited to Brawn Biotech Limited has been passed.

(iii) No Special resolution is proposed to be conducted through Postal Ballot.



Means of Communication

- Quarterly Results: Dissemination through publication in newspaper as required under Listing Agreement.
- Newspapers wherein results normally published -Business Standards (in Hindi) and Business 2. Standards (in English)
- The financial results and official news releases are also available on the company's website at www.brawnpharma.com

GENERAL SHAREHOLDERS INFORMATION

(i) Details of Forthcoming Annual General Meeting

Date

30th September, 2011

Time

04.00 P.M.

Venue

The Executive Club", 439, Vill - Shahoorpur, P.O. - Fatehpur Beri, New Delhi-110074

Financial year	The financial year of the company is for a period of 12 months from 1 st April to 31 st March every year.				
Date of Book Closure	24-09-2011 to 30-09-2011				
Listing on Stock Exchanges	Bombay Stock Exchange Limited; Delhi Stock Exchange Limited				
Financial Calendar (Tentative)	 Results for the Quarter ending June'11- mid of Aug' 11 Results for the Quarter ending Sep'11- mid of Nov' 11 Results for the Quarter ending Dec'11- mid of Feb' 12 Results for the Quarter ending Mar'12- mid of May' 12 				
Registrar and Share Transfer Agent	M/s. RCMC Share Registry Private Limited B-106, Sector-2, Noida,-201301 (U.P.)				
Dematerialisation of Shares	11,40,547 shares i.e. 38.01% (As on 31.03.2011)				
Address for Correspondence	4/4B, Asaf Ali Road, Old Delhi Stock Exchange Building, New Delhi-110002, Phone: 32911528, 32911529, Fax: 011 -23275208				

(ii) Distribution of Shareholding as on 30.06.2011

Shareholding of	Shareh	olders	Share holdin		gs	
value of Rs.	Number	% to total	Shares	Amount	% to total	
UPTO TO 5000	6282	93.34	776272	7762720.00	25.87	
5001 TO 10000	203	3.02	171739	1717390.00	5.72	
10001 TO 20000	131	1.95	217911	2179110.00	7.26	
20001 TO 30000	49	0.73	129995	1299950.00	4.33	
30001 TO 40000	13	0.19	45838	458380.00	1.53	
40001 TO 50000	12	0.18	55839	558390.00	1.86	
50001 TO 100000	15	0.22	105298	1052980.00	3.51	
100001 and Above	25	0.37	1497408	14974080.00	49.91	
** G Total	6730	100.00	3000300	30003000.00	100.00	



Cate- gory code	Category of shareholder	Number of share- holders	Total Number of Shares	Number of shares held in demateriali	Total Share as a percen total no. of	tage of	or othe	Shares Pledged or otherwise encumbered	
.			an a	zed form	As a percantage of (A+B)	As a percentage of	No.of shares	As a percentage	
(I)	(II)	(III)	(IV) 	(V)	(VI)	(A+B+C) (VII)	(VIII)	(IX)=(VIII /(IV)*100	
(A)	Shareholding of promoter and promoter Gre	oup		1					
(1)	Indian								
(a)	INDIVIDUALS/HUF	33	12,68,850	1,12,650	42.29	42.29	0	0.00	
(b)	CENTRAL GOVERNMENT/STATE GOVERNMENT	0	0	0	0.00	0.00	0	0.00	
(c)	BODIES CORPORATE	1	68,100	0	2.27	2.27	0	0.00	
(d)	FINANALCIAL INSTITUTIONS/BANKS	.0	0	0	0.00	0.00	0	0.00	
(e)	ANY OTHER (SPECIFY)- DIRECTORS & RELATIVES	0	0	0	0.00	0.00	0	0.00	
	Sub-Total (A) (1)	34	13,36,950	1,12,650	44.56	44.56	0	0.00	
(2)	Foreign								
(a)	INDIVIDUALS(NRI)/FOREIGN INDIVIDUALS	0	0	0	0.00	0.00	0	0.00	
(ъ)	BODIES CORPORATE	0	. 0	0	0.00	0.00	0	0.00	
(c)	INSTITUTIONS	0	0	0	0.00	0.00	0	0.00	
(d)	ANY OTHER (SPECIFY)	0	0	0	0.00	0.00	0	0.00	
	Sub-Total (A) (2)	0	0	0	0.00	0.00	0	0.00	
	Total (A)	34	13,36,950	1,12,650	44.56	44.56	0	0.00	
(B)	Public shareholding	L			1				
(1)	Institutions			· · · · · · · · · · · · · · · · · · ·					
(a)	MUTUAL FUNDS/UTI	5	17,800	0	0.59	0.59	0	0.00	
(b)	FINANCIAL INSTITUTIONS/BANKS	o	0	0	0.00	0.00	0	0.00	
(c)	CENTRAL GOVERNMENT/STATE GOVERNMENT	0	0	0	0.00	0.00	0	0.00	
(d) ·	VENTURE CAPITAL FUND	0	0	0	0.00	0.00	0	0.00	
(e)	INSURANCE COMPANIES	0	0	0	0.00	0.00	0	0.00	
(f)	FOREIGN INSTITUTIONAL INVESTORS	0	0	0	0.00	0.00	0	0.00	
(g)	FOREIGN VENTURE CAPITAL INVESTORS	0	0	0	0.00	0.00	0	0.00	
(h)	ANY OTHER SPECIFY	0	0	0	0.00	0.00	, 0	0.00	
	Sub-Total (B)(1)	5	17,800	0	0.59	0.59	0	0.00	
(2)	Non-institutions	<u> </u>				L			
(a)	BODIES CORPORATE	78	1,19,071	1,15,371	3.97	3.97	0	0.00	
(b)	i) INDIVIDUALS -HOLD UPTO I LAKH (NOM VALUE)	6544	12,83,912	7,98,859	42.79	42.79		0.00	
	ii) INDIVIDUALS -HOLD ABOVE 1 LAKH (NOM VALUE)	6	1,42,645	72,845	4.75	4.75		0.00	
(c)	ANY OTHER (SPECIFY)- A) CLEARING MEMBERS	14	8,376	8,376	0.28	0.28	0	0.00	
/	B) NON-RESIDENTS	49	91,546	35,346	3.05	3.05	0	0.00	
	C) TRUST	9	0	33,340	0.00	0.00	0	0.00	
	Sub-Total (B) (2)	6691	16,45,550		54.84		0		
		 		10,30,797	 	54.84		0.00	
	Total (B)	6696	16,63,350	10,30,797	55.43	55.43	. 0	0.00	



Cate- gory code	Category of shareholder	Number of share- holders	Total Number of Shares	Number of shares held in demateriali	Total Share as a percen total no. of	tage of	Shares or othe encum	
(I)	(II)	(III)	(IV)	zed form (V)	As a percantage of (A+B) (VI)	As a percent- age of (A+B+C) (VII)	No.of shares (VIII)	As a percentage (IX)=(VIII) /(IV)*100
(C)	Shares held by Custodians and against which	:h						
	Depository Receipts have been issued			-		_		
	SHARES HELD BY CUSTODIANS	0	0	. (0.00	0.00	0	0.00
	Sub-Total (C)	0	0	(0.00	0.00	. 0	0.00
*.	Total (C)	0	0	(0.00	0.00	0	0.00
	Grand-Total	6730	30,00,300	11,43,44	7 100.00	100.00	0	0.00

Code of Conduct

As required by clause 49 I (D) of the Listing Agreement, the Company has formulated a Code of Conduct for ail Directors and Senior Management of the Company and the same has been adopted by the Board. The Code is also available on the Company's official website. All the Directors and Senior Management Personnel have affirmed compliance with the said Code of Conduct.

CEO/CFO Certification

The Company is duly placing a certificate to the Board from the Chairman and Managing Director in accordance with the provisions of clause 49 (V) of the Listing Agreement. The aforesaid certificate duly signed by the Chairman and Managing Director in respect of the financial year ended 31st March`11 has been placed before the board in the meeting held on 31st May, 2011.

Declaration

The Board of Directors of the Company has adopted the Code of Conduct for Director and Senior Management of the Company.

All the Board Members and Senior Management Personnel have affirmed their Compliance with the respective Codes.

Brij Raj Gupta

Chairman & Managing Director



CERTIFICATE OF COMPLIANCE FROM A PRACTISING CHARTERED ACCOUNTANT STIPULATED UNDER CLAUSE 49 OF THE LISTING AGREEMENT

To
The Members of
Brawn Biotech Limited
(Formerly Brawn Pharmaceuticals Limited)

We have examined the compliance of conditions of Corporate Governance by Brawn Biotech Limited (Formerly Brawn Pharmaceuticals Limited) for the year ended on 31st March, 2011, as stipulated in Clause 49 by the Listing Agreement of the said Company with the Stock Exchanges.

The Compliance of conditions of Corporate Governance is the responsibility of the management. Our examination has been limited to a review of the procedures and implementations thereof, adopted by the company for ensuring the compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion of the financial statements of the Company.

We state that in respect of investor grievances received during the year ended 31st March, 2011, no investor grievances are pending for a period exceeding one month against the Company as per the records maintained by the Company.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness, which the management has conducted the affairs of the company.

In our opinion and to the best of our information and according to the explanations given to us, and the representations made by the directors and management, we certify that Company has generally complied with the condition of Corporate Governance as stipulated in Clause 49 of the above-mentioned Listing Agreement.

Place: New Delhi Date: 03.09.2011 For Satinder Saini & Co Chartered Accountants Registration No. 008834N Sd/-(S.K.Saini) Proprietor M.No. 87357

AUDITORS' REPORT

To the Members of M/s Brawn Biotech Limited

- 1. We have audited the attached Balance Sheet of M/s Brawn Biotech Limited (Formerly Known as Brawn Pharmaceuticals Limited) as at March 31, 2011 and also the Profit and Loss account and the cash flow statement for the year ended on that date, annexed thereto. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.
- 2. We conducted our audit in accordance with auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
- 3. As required by the Companies (Auditor's Report) Order, 2003 issued by the Central Government of India in terms of Sub-Section (4A) of Section 227 of the Companies Act, 1956, we enclose in the Annexure, a statement on the matters specified in paragraphs 4 and 5 of the said Order.
- 4. Further to our comments in the Annexure referred to above and subject to Note No. 2(E) of Schedule 13, we report that:
- We have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit.
- ii. In our opinion, proper books of account as required by law have been kept by the Company, so far as appears from our examination of those books:
- iii. The Balance Sheet, Profit and Loss Account and Cash Flow Statement dealt with by this report are in agreement with the books of account;
- iv. In our opinion, the Balance Sheet and Profit and Loss Account and Cash Flow Statement dealt with by this report comply with the Accounting Standards referred to in Sub - Section (3C) of Section 211 of the Companies Act. 1956.
- v. On the basis of the written representations received from the Directors, as on March 31, 2011 and taken on record by the Board of Directors, we report that none of the Directors is disqualified as on March 31, 2011 from being appointed as a director in terms of clause (g) of Sub-Section (1) of Section 274 of the Companies Act, 1956.
- vi. In our opinion and to the best of our information and according to the explanations given to us, the said accounts read with notes give the information required by the Companies Act, 1956, in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India;
- a) in the case of the Balance Sheet, of the state of affairs of Company as at March 31, 2011;
- b) in the case of the Profit and Loss Account, of the profit earned for the year ended on that date; and
- in the case of Cash Flow Statement, of the cash Flow for the year ended on that date.

Place: New Delhi Date: 03.09.2011 For Satinder Saini & Co Chartered Accountants Registration No. 008834N Sd/-(S.K.Saini) Proprietor

M.No. 87357

Brawn Biotech Ltd.

Annexure referred to in paragraph [4] of our report of even date

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets on the basis of the information made available.
- (ii) (a) As explained to us, inventories have been physically verified by the management in accordance with perpetual inventory program at regular intervals during the year which in our opinion is reasonable.
 - (b) The procedures of physical verification of inventory followed by management are, in our opinion reasonable and adequate in relation to the size of the Company and the nature of its business.
 - (c) The company has maintained proper record of inventory. As explained to us the discrepancies noticed on verification between the physical stock and the book records were not material.
- (iii) (a) As informed to us, the Company has not taken/granted loans, secured or unsecured to/from companies, firms or other parties covered in the register maintained under Section 301 of the Company's Act, 1956. Consequently the requirements of clauses (iii) (f) and (iii) (g) of paragraph 4 of the order are not applicable.
- (iv) In our opinion and according to the information and explanations given to us, there is an adequate internal control procedure commensurate with the size of the Company and the nature of its business, for the purchase of inventory and fixed assets and for the sale of goods. During the course of our audit, we have not observed any continuing failure to correct major weakness in internal controls.
- (v) (a) According to the information and explanations given to us there is no contract or arrangement referred to in Section 301 of the Act, which are required to be entered in the register maintained under the said Section.
 - (b) Accordingly, the provision of the clause v (b) of the Companies (Auditor's Report) Order, 2003 is not applicable to the company.
- (vi) According to the information and explanation given to us the company has not accepted any deposits from the public during the year. Therefore the provisions of clause (vi) of paragraph 4 of the order are not applicable to the company.
- (vii) In our opinion, the company has an internal audit system commensurate with the size and nature of its business.
- (viii) To the best of our knowledge and as explained, the Central Government has not prescribed the maintenance of cost records under clause (d) of sub section (1) of Section 209 of the Companies Act, 1956 for the products of the Company.
- (ix) According to the company records, the company is regular in depositing with appropriate authorities undisputed statutory dues including, Income Tax, Sales Tax, Service Tax, Wealth Tax, Custom Duty, Excise Duty, Cess & other material statutory dues applicable to it. There is no outstanding with respect to undisputed dues as of the last of the financial year concerned for a period of more than six months from the date they became payable.



Brawn Biotech Ltd.

- (x) The company has accumulated losses at the end of the financial year aggregating to Rs. 96.04Lac. The company has not incurred cash losses during the financial year covered by the audit and in the immediately preceding financial year.
- (xi) Based on our audit procedures and according to the explanation given to us, we are of the opinion that the company has not defaulted in repayment of dues to financial institutions, banks. The company has not issued any debentures.
- (xii) According to the information and explanations given to us, and based on the documents and records produced to us, the company has not granted loans and advances on the basis of security by way of pledge of shares, debentures and other securities.
- (xiii) In our opinion, the company is not a chit fund or a nidhi mutual benefit fund/society. Accordingly the provision of clause 4(xiii) of the Companies (Auditor's Report) Order, 2003 are not applicable to the Company.
- (xiv) The company does not deal or trade in shares, securities, debentures and other investments.
- (xv) Based on the information and explanations given to us by management, the company has not given the guarantees for loans by others from the banks & financial institutions.
- (xvi) The company has not raised any term loan during the year.
- (xvii) According to the information and explanations given to us, and on overall examination of the balance sheet of the Company, we report that no funds raised on short-term basis have been used for long-term investment by the Company.
- (xviii) The Company has not made any preferential allotment of shares to parties or companies covered in the register maintained under section 301 of the Companies Act, 1956.
- (xix) The Company has not issued any secured debentures.
- (xx) The Company has not raised any money through public issue during the year.

Based upon the audit procedures performed and information and explanations given by the management, we report that no fraud on or by the Company has been noticed or reported during year.

Place: New Delhi Date: 03.09.2011 For Satinder Saini & Co Chartered Accountants Registration No. 008834N Sd/-(S.K.Saini) Proprietor M.No. 87357

BALANCE SHEET AS AT 31ST MARCH, 2011

	PARTICULARS	SCHEDULE	RUPEE\$ 31.03.11	RUPEES 31.03.10
l)	SOURCE OF FUNDS			
	SHARE HOLDERS' FUNDS			
	(A) Share Capital	1	30,003,000.00	30,003,000.00
	(B) Reserves & Surplus	2	21,195,500.00	21,195,500.00
	(C) Unsecured loan		3,000,000.00	•
	Total		54,198,500.0 0	51,198,500.00
H)	APPLICATION OF FUNDS			
1	FIXED ASSETS	3		
	Gross Block		328,825.00	126,300.00
	Less: Accumulated Depreciation		59,263.15	27,137.00
	Net Block		269,561.85	99,163.00
2	INVESTMENTS	4	300,000.00	300,000.00
3	CURRENT ASSETS, LOANS & ADVANCES			
	(A) Sundry Debtors	5	61,678,135.86	32,011,112.84
	(B) Cash & Bank Balances	6	1,573,642.96	277,254 .03
	(C) Loans & Advances	7	4,960,750.26	593,151.39
	(D) Inventory		23,927,163.00	
			92,139,692.08	32 ,881,518.2 6
	LESS: CURRENT LIABILITIES & PROVISIONS	8	54,595,747.56	1,683,262.53
	NET CURRENT ASSETS		41,650,707.52	35,338,255.74
	PROFIT AND LOSS ACCOUNT	9	9,604,157.45	11,738,697.27
	DEFERRED TAX ASSETS		2,374,073.18	3,722,384.00
	Total		54,198,500.00	51,198,500.00
OTE	S TO ACCOUNTS ANNEXED	13		

AS PER OUR REPORT OF EVEN DATE ATTACHED

For and on behalf of the board of Directors

For Satinder Saini & Company

Chartered Accountants Firm Regn No. 008834N


Sd/-(S. K. Saini) Propreitor M.No. 87357

Place: New Delhi Date: 03.09.2011

Sd/-(B.R.Gupta) **Managing Director**

Sd/-(Brij Bala Gupta) Director

Sd/-(Amit Bansal) Company Secretary



PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH, 2011

PARTICULARS	SCHEDULE	RUPEES	RUPEES
		31.03.11	31.03.10
INCOME			
Sales		161,173,858.06	9,535,338.24
Other Income		130.667.00	3,029,473.46
Total		161,304,525.06	12,564,811.70
EXPENDITURE			
Cost of Goods Sold	10	86,594,585.44	8,162,646.45
Salaries & Other benefits	11	37,108,034.00	1,846,250.00
Other Expenses	12	33,448,787.67	1,360,133.95
Depreciation	3	32,126.15	18,121.00
Total		157,183, 53 3.2 6	11,387,151.40
Profit/Loss before Taxation		4,120,991.80	1,177,6 6 0.30
Provision for Income Tax		638,141.16	82,018.0
Add: Written back of Deferred Tax Assets		(1,348,310.82)	3,722,384.0
Profit after Tax		2,134,539.82	4,818,026.2
Add: Balance brought forward from Previous Year		(11,738,697.27)	(16,556,723.52
Amount Available for Appropriation		(9,604,157.45)	(11,738,697.27
APPROPRIATION			
Transfer to General Reserve		-	-
Transfer to Balance Sheet		(9,604,157.45)	(11,7 3 8,697.27
Earning Per Share		1.16	0.37

NOTES TO ACCOUNTS ANNEXED

13

AS PER OUR REPORT OF EVEN DATE ATTACHED

For and on behalf of the board of Directors

For Satinder Saini & Company

Chartered Accountants Firm Regn No. 008834N

Sd/-(S. K. Salni) Propreitor M.No. 87357 Sd/-(B.R.Gupta) Managing Director Sd/-(**Brij Bala Gupta**) Director

Place: New Delhi Date: 03.09.2011 Sd/-(Amit Bansal) Company Secretary

SCHEDULE - 1		
•	RUPEES	RUPEES
SHARE CAPITAL	31.03.11	31.03.10
AUTHORISED	1	
45,00,000 EQUITY SHARE OF RS 10 EACH	45,000,000.00	45,000,000.00
ISSUED, SUBSCRIBED & PAID UP		
30,00,300 EQUITY SHARE'S OF RS 10 EACH FULLY PAID UP	30,003,000.00	30,003,000.00
TOTAL	30,003,000.00	30,003,000.00
SCHEDULE - 2		
	RUPEES	RUPEES
RESERVES & SURPLUSES	31.03.11	31.03.10
SHARE PREMIUM ACCOUNT	15,201,500.00	15,201,500.00
3,60,000 Equity Shares of Rs 10/- each issued		
At a premium of Rs 15/- each	v	
19,60,300 Equity Shares of Rs 10/- each issued		
At a premium of Rs 5/- each		
INVESTMENT ALLOWANCE RESERVE	150,000.00	150,000.00
GENERAL RESERVE	5,844,000.00	5,844,000.00
TOTAL	21,195,500.00	21,195,500.00

26th Annual Report 2010 - 2011


SCHEDULE-3

FIXED ASSETS SCHEDULE AS PER SCHEDULE XIV OF COMPANIES ACT 1956

PARTICULARS	GROSS BLOCK	RATE OF DEP	ADDITIONS	DEDUCTIONS	TOTAL	DEPRECIATION	DEDUCTIONS	FOR THE YEAR	TOTAL	NET BLOCK	NET BLOCK
	ON 1.04.20010					UP TO 31.03.2010		2010-11		AS ON 31.03.2011	AS ON 31.83.2010
COMPUTER	126,300.00	16.21	150,625.00		276,925.00	27,137.00	:	30,048,30	57,185.30	219,739.70	99,163.00
AIR CONDITIONERS & REFRIGERATION		6.33	27,000.00		27,900.00	•		1,217.44	1,217.44	25,782.56	•
MOBILE / TELEPHONE INSTRUMENTS		6.33	4,900.00	-	4,800.00			201.40	201.40	4,698.60	
OFFICE EQUIPMENT		6.33	20,600.00		20,900.00	•		659.01	659.01	19,340.99	
TOTAL	126,300.00		202,525.00	•	328,825.00	27,137.00		32,126.15	59,263.15	269,561.85	99,163.00



SCHEDULE - 4			
•		RUPEES	RUPEES
INVESTMENTS		31.03.11	31.03.10
LONG TERM INVESTMENTS			
(OTHER THAN TRADE)			
UNQUOTED (A Company under the same Management)			
30,000 EQUITY SHARES OF RS 10 EACH		300,000.00	300,000.00
M/S BRAWN LABORATORIES LTD, FULLY PAID UP			
(Market Price not ascertainable)			
TOTAL		300,000.00	300,000.00
SCHEDULE - 5			
		RUPEES	RUPEES
SUNDRY DEBTORS		31.03.11	31.03.10
A) DEBTORS OUTSTANDING FOR A PERIOD EXCEEDING SIX MONTHS		27,020,654.73	27,040,303.63
B) OTHER DEBTORS		34,657,481.13	4,970,809.21
TOTAL		61,678,135.86	32,011,112.84
SCHEDULE - 6			
		RUPEES	RUPEES
CASH & BANK BALANCES		31.03.11	31.03.10
CASH IN HAND		75,937.96	208,463.96
BALANCE IN CURRENT ACCOUNTS		1,497,705.00	68,790.07
SCHEDULE - 7		1,573,642.96	277,254.03
		RUPEES	RUPEES
LOANS & ADVANCES		31.03.11	31.03.10
DEPB RECOVERABLE (ADVANCES RECOVERABLE IN CASH OR IN KIND		4,140,000.00	4,140,000.00
OR FOR VALUE TO BE RECEIVED)			
SECURITY DEPOSITS		313,602.00	313,602.00
OTHER DEPOSITS	•	154,808.19	121,341.32
TAX DEDUCTED AT SOURCE		155,776.07	155,708.07
PRE-PAID EXPENSES		85, 3 52.00	2,500.00
STAFF IMPREST / ADVANCES		4,251,212.00	<u> </u>
TOTAL		4,960,75 0 .26	593,151.39



Brawn Biotech Ltd.

CURRENT LIABILITIES & PROVISIONS SUNDRY CREDITORS & EXPENSES PAYABLE ADVANCE FROM CUSTOMERS STATUTORY LIABILITIES PAYABLE PROVISION FOR INCOME TAX	RUPEES 31.03.11	RUPEES 31.03.10
SUNDRY CREDITORS & EXPENSES PAYABLE ADVANCE FROM CUSTOMERS STATUTORY LIABILITIES PAYABLE		
ADVANCE FROM CUSTOMERS STATUTORY LIABILITIES PAYABLE		<u> </u>
ADVANCE FROM CUSTOMERS STATUTORY LIABILITIES PAYABLE	40,939,757.06	1,157,629.10
STATUTORY LIABILITIES PAYABLE	• •	1, 137,029.10
	10,163,881.29	440.070.00
	1,648,939.00	410,378.38
PROVISION FOR INCOME TAX	798,159.21	82,018.05
PROVISION FOR GRATUITY	6 3 5,938.00	33,237.00
PROVISION FOR LEAVE ENCASHMENT	409,073.00	•
TOTAL	54,595,747.56	1,683,262.53
SCHEDULE - 9		
MISCELLANEOUS EXPENDITURE	RUPEES	RUPEES
(TO THE EXTENT NOT WRITTEN OFF OR ADJ)	31.03.11	31.03.10
PROFIT & LOSS ACCOUNT		
OPENING BALANCE	11,738,697.27	16,556,723.52
LESS: CURRENT YEAR PROFIT & LOSS ACCOUNT	2,134,539.82	4,818,026.26
BALANCE CARRIED FORWARD	9,604,157.45	11,738,697.27
·		
SCHEDULE - 10	RUPEES	RUPEES
PURCHASE / COST OF GOODS SOLD	31.03.11	31.03.10
OPENING STOCK		
PURCHASES	110,521,748.44	8,162,646.45
SUB TOTAL	110,521,748.44	8,162,646.45
LESS CLOSING STOCK	23,927,163.00	0,102,040.40
COST OF GOODS SOLD	86,594,585.44	8,162,646.45
COST OF GOODS SOLD	00,354,363.44	0,102,040.43
SCHEDULE - 11		
	RUPEES	RUPEES
PERSONNEL EXPENSES	31.03.11	31.03.10
SALARY & WAGES	13,493,769.00	766,929.00
	1,108,444.00	63,900.00
BONUS	1,108,444.00 6 3 5,938.00	7,979.00
GRATUITY	·	1,919.00
LEAVE ENCASHMENT	415,004.00	1,007,442.00
OTHER ALLOWANCES	21,454,879.00	
TOTAL	37,108,034.00	1,846,250.00

26th Annual Report 2010 - 2011



Brawn Biotech Ltd.

SCHEDULE - 12		
OTHER EXPENSES	RUPEES	RUPEES
(SELLING & ADMINISTRATIVE EXPENSES)	31.03.11	31.03.10
ADDITIONAL DEMAND P.F	-	379,824.00
ADVERTISEMENT EXPENSES	863,092.00	29,733.00
AGM EXPENSES	9,706.00	8,824.00
AUDIT FEES	60,665.00	44,120.00
BREAKAGE & EXPIRY	1,280,739.91	-
BUSINESS PROMOTON EXPENSES	3,227,684.00	-
COMMISSION PAID	4,990,843.06	-
COMPUTER MAINTAINENCE	126,565.00	-
CONVEYANCE EXPENSES.	93606.00	4,782.00
DIRECTORS SITTING FEES	•	13,650.00
DISCOUNT EXPENSES	1,753,546.79	-
FREIGHT & CARTAGE	2,900,399.00	281,814.00
INSURANCE EXPENSE	45,789.00	-
GENERAL EXPENSES	271,445.00	-
INPUT VAT REVERSE	1,292,600.12	-
INTEREST & BANK CHARGES	425,934.33	10,193.33
LEGAL & PROFESSIONAL FEES	225,508.00	244,515.00
LISTING & FILING FEE	44,120.00	31,765.00
MEMBERSHIP FEES	16,493.00	2,500.00
OFFICE EXP.	128,342.00	1,720.00
OTHER EXPENSES	752,277.46	22.62
POSTAGE, AND COMMUNICATION EXPENSES	613,618.00	38,381.00
PRINTING & STATIONERY	368,807.00	33,172.00
OCTROI EXPENSES	147,160.00	-
REPAIR & MAINTAINENCE	43,987.00	-
REGISTRATION & LICENCE FEES	171,470.00	3,750.00
RENT	948,576.00	180,000.00
SHARE MANAGEMENT EXPENSES	30,037.00	8,506.00
STAFF WALFAIR EXPENSES	67,593.00	3,928.00
TELEPHONE EXP.	1,448,645.00	6,152.00
TESTING CHARGES	17,503.00	3 2,782.00
TRAVELLING EXPENSES	11,082,036.00	-
TOTAL	33,448,787.67	1,360,133.95



SCHEDULE-'13'

SCHEDULE FORMING PART OF THE BALANCE SHEET AND PROFIT & LOSS ACCOUNT

1. SIGNIFICANT ACCOUNTING POLICIES

(A) GENERAL

The accounts are prepared on historical cost basis as a going concern following the mercantile system of accounting and recognizing income and expenditure on accrual basis. Accounting policies not specifically referred to otherwise are consistent and in concurrence with generally accepted accounting principles.

(B) VALUATION OF INVENTORIES

Inventories are valued at cost or market price whichever is lower.

(C) FIXED ASSETS AND DEPRECIATION

Fixed assets are stated at cost less accumulated depreciation. Depreciation on fixed assets is provided on straight-line method at the rates and in the manner provided in schedule XIV to the Companies Act, 1956.

(D) INVESTMENTS

Investments are stated at cost of acquisition.

(E) REVENUE RECOGNITION

(i) Sales

Sales are recognized when effectively the risk and rewards of ownership has passed to the buyer.

(ii) Commission/Fee/Discount Income

Commission / Fee/ Discount Income is accounted as and when accrued and realizable upon raising of bills.

(F) FOREIGN EXCHANGE TRANSACTION

Transactions in foreign currency are recorded at the exchange rate prevailing at the time of such transactions. Realized gains or losses on foreign exchange transactions are recognized in the Profit and Loss account at the time of actual realization of gains/losses.

(G) CONTINGENT LIABILITIES

Liabilities below Rs. 1,00,000/- if any are not recognized as contingent liability.

2. NOTES TO ACCOUNTS:

(A) CONTINGENT LIABILITIES NOT PROVIDED FOR

(i) Claims against the company not acknowledged as debts: Nil

(iii) Estimated amounts of contracts remaining to be executed on Capital Accounts and not provided for Nil (Previous Year Nil)

(B) IN THE OPINION OF DIRECTORS

- (a) The current assets and loans and advances are approximately of value stated if realized in the ordinary course of business except to the extent of impairment, if any.
- (b) The provision for all known liabilities is adequate and considered reasonable.
- (C) Balances of Sundry Debtors, Creditors and other Advances are subject to confirmation/reconciliation and consequential adjustment if any arising there to shall be considered in due course of time.

(D) RETIREMENT BENEFITS

Liability for Gratuity and leave encashment is being provided based upon the certificate of Acturian at the end of the year.

(E) Refer Schedule -7, The Company has recognized recoverable claim of Rs.41.40 Lac (Rs.41.40 Lac), arised on account of custom duty credit on export sales. These claims are recoverable subject to receipt of export payments, which are overdue and under litigation. The management considered these debtors as good and hence no provision is considered necessary.



(F)	Managerial Remuneration : Remuneration to Directors Sitting Fees	Nil Rs.14,550/-	(Nil) (Rs.13,650/-)
(G)	Auditor's Remuneration: Audit Fee Tax Matters TOTAL	Rs. 44,120/- Rs.16,545/- Rs.60,665/-	(27,575/-) (16,545/-) (44,120/-)
(H)	The deferred tax assets comprises of the following: I. Deferred Tax Liabliity Related to Fixed Assets	Rs. 2 0202.19	(17800.00)
	ii. Deferred Tax Assets Related to Brought Forward/carried forward of business losses andUnabsorbed depreciation Net Deferred Tax Assets	Rs.23,94,275.37 Rs.23,74,073.18	(3740184.00) (3722384.00)

(l) Related Party Disclosure

(a) Related party disclosures as required to by AS -18 are given below:

Companies/Firms in which Directors & their relative are interested:

Name of Concern

M/S Brawn Laboratories Ltd.

M/S Overseas Laboratories (P) Ltd.

M/S Delhi Pharma

M/S Fine Pharmachem

Directors:

Mr. Brij Raj Gupta

Mrs. Brij Bala Gupta

Mrs. Urmila Gupta

Mr.Mahesh Kumar Nanchal

Mr. Manohar Lai

Mr. Bal Kishan Sharma

Relatives of Director:

Mr. A.K.Gupta

Mrs.Shashi Bala Gupta

Dr. Atul Gupta Mr. Nitin Gupta Mr. Love Gupta

Mr. Kush Gupta

Relationship

Associate Company by virtue of Common Directors Associate Company by virtue of Common Directors Associate firm by virtue of relative of Director is proprietor Associate firm by virtue of relative of Director is proprietor

Transactions with related party:

S.No.	Name of Company/Firm	Nature of Transactions	Amount (F	Rs. In Lac)
1.	M/s Brawn Laboratories Ltd.	Purchases ,	546.12	(81.63)
2.	M/s Brawn Laboratories Ltd.	Sales	1.76	(Nil)
3.	M/s Delhi Pharma	Sales	14.70	(0.90)



- (J) Segment Reporting (AS-17)
- Primary Segment: The identification of Business segment is done in accordance with the system adopted for internal financial reporting to the board of directors and management structure. The company has identified products as primary segment.
- 2. Secondary Segment: The company had operated in one more geographical area in addition to primary segment.

	Particulars	Pharmaceuticals Products	Fabric	Consolidated Total
A-	Revenue/Sales	12,11,48,634.06	4,00,25,224.00	16,11,73,858.06
B-	Cost of Goods Sold	5,05,31,858.44	3,60,62,727.00	8,65,94,585.44
C-	Net Revenue	7,06,16,775.62	39,62,497.00	7,45,79,272.62
D-	Operating Expenses	7,03,60,968.82	5,27,979.00	7,05,88,947.82
E-	Operating Profit	5,55,806.68	34,34,518.00	39,90,324.80
F-	Add: Discount Income	1,29,967.00	Nil	1,29,967.00
G-	Other Income	700.00	Nil	700.00
H-	Ner Profit/Loss	6,86,473.38	34,34,518.00	41,20,991.80
ĺ-	Segment Assets	5,02,36,003.00	39,62,497.00	5,41,98,500.00
J-	Segment Liabilities	5,41,98,500.00	Nil	5,41,98,500.00

(K)	Earning Per Share		(Rs. In Lacs)
` '	•	2010-2011	` 2009-2010 [´]
	Profit/(Loss) after Tax	34.83	10.96
	As per Profit & Loss Account		
	Number of Equity Share	3000300	3000300
	Earnings/ (Loss) Per Shares	1.16	0.37

- (L) There is no amount remaining unpaid to Small Scale Suppliers within the meaning of "The interest on Delayed Payments to Small Scale and Ancillary Undertaking Act".
- (M) Additional information pursuant to provisions of paragraph 3 & 4 of part (ii) schedule (vi) to the Companies Act, 1956 (As certified by the management and accepted by the auditors).
- (a) The Company had no manufacturing activities during the year. The company got its products manufactured from other parties and hence the information regarding installed capacity is not given.
- (b) Sales and purchases of goods Class of goods

Class of Traded Goods	unit	Purc	hases	S	ales
		Quantity	Value (Rs)	Quantity	Value (Rs)
TABLETS	Nos.	11488460	42159991.87	9544350	78168700.84
CAPSULES	Nos.	5767080	21163850.15	4533560	28250367.33
LIQUID/ORAL/SYRUP/DROPS	Nos.	1357490	4981674.42	1185080	7384692.23
INJECTION	Nos.	1388360	5094960.18	993570	6191319.28
OINTEMENTS	Nos.	18470	67780.62	16080	100200.70
SACHETS	Nos.	269980	990764.17	169040	1053353.67
SUITING FABRICS	Mtrs	377113	36062727.00	377113	40025224.00

(The above figures are prepared and certified and being technical matter relied upon by Auditors)



(N) The variation in profit shown in unaudited results/ published is due to reversal of VAT recoveries and provisions for retiremental benefits as on date of 31st March 2011.

(O)	Amo	ount remitted in foreign currency	Value	(Rs. In Lac)
•	(a)	Expenditure in foreign currency	NIL	(NIL)
		Traveling expense	NIL	(NIL)
	(b)	Value of imports on CIF basis	NIL	(NIL)
	(c)	Earning in foreign currency		
	• •	Export of good	70.87	(58.72)
		(Previous year figures in Brackets)		

(P) Previous year's figures have been regrouped/rearranged wherever necessary to make them comparable with current year figures.

AS PER OUR REPORT OF EVEN DATE

For and on behalf of the board of Directors

For Satinder Sain! & Company

Chartered Accountants Regn. No. 008834N

Sd/-	Sd/-	Sd/-
(S. K. Saini)	(B.R.Gupta)	(Brij Bala Gupta)
Propreitor	Managing Director	Director
M No. 97257		

Place: New Delhi (Amit Bansal)
Date: 03.09.2011 Company Secretary



CASH FLOW STATEMENT

(PURSUANT TO CLAUSE 32 THE LISTING AGREEMENT WITH STOCK EXCANGE)

A .)	NET CASH FLOW FROM OPERATING ACTIVITIES	FOR THE YEAR ENDED ON 31.03.2011	FOR THE YEAR ENDED ON 31.03.2010
	NET PROFIT (LOSS) FROM OPERATING ACTIVITY NET PROFIT (LOSS)AFTER TAX	4,831,161.46	1,095,642.26
	ADJUSTMENTS FOR LOSS ON SALE OF ASSETS ASSETS WRITTEN OFF INTEREST PAID DEPRECIATION PRILIMINARY EXPENSES WRITTEN OFF OPERATING PROFIT (LOSS) BEFORE WORKING CAPITAL CHANGES	32,126.15 	18,121.00
	ADJUSTMENTS FOR WORKING CAPITAL CHANGES	-	
	Increase/Decrease in Sundry Debtors Increase/Decrease in Inventory Increase/Decrease in Current Liabilities Increase/Decrease in Deferred Tax	(29,667,023.02) (23,927,163.00) 52,945,722.03 (1,348,310.82)	1,201,307.16 2,555,104.60 (4,645,808.25)
	NET CASH FROM OPERATING ACTIVITIES A	2,866,512.81	224,366.77
В.)	CASH FLOW FROM INVESTMENT ACTIVITIES Purchase of Fixed Assets Capital work-in Progress Proceed form sale of fixed Assets NET CASH USED IN INVESTMENT ACTIVITY B	(202,525.00)	(14,750.00)
c.)	CASH FLOW FROM FINANCE ACTIVITY Proceed from Issue of Share Capital Payment of Borrowings Proceed from Unsecured Ioan Increase In Loans & Advances Payment of interest NET CASH USED IN FINANCE ACTIVITY C	3,000,000.00 (227,598.87) - 2,772,401.13	-
	CASH FLOW DURING THE YEAR (A+B+C)	1,296,388.94	209,616.77
	Cash & Cash Equivalent (Opening Balance) Cash & Cash Equivalent (Closing Balance)	277,254.03 1,573,642.97	67,637.26 277,254.03

For and on behalf of the Board of Directors

Sd/-

(B.R.Gupta) Managing Director

Sd/-(Brij Bala Gupta) Director

Sd/-

(Amit Bansal) Company Secretary

The Board of Directors BRAWN BIOTECH LTD.

Place: New Delhi

Date: 03.09.2011

AUDITORS' CERTIFICATE

We have examined the cash flow statement of BRAWN BIOTECH LTD. for the year ended 31st March, 2011. The statement has been prepared by the company in accordance with the listing agreement with the stock exchanges and is based on and in agreement with the corresponding Profit & Loss account and Balance Sheet of the company covered by our report of 03.09.2011 to the members of the company.

For Satinder Saini & Company Chartered Accountants

Firm Regn No. 008834N

Sd/-(S. K. Saini) **Proprietor** M. No.87357

Place: New Delhi Date: 03.09.2011



Date: 03-09-2011

BALANCE SHEET ABSTRACT AND COMPANY'S GENERAL BUSINESS PROFILE

(As per Schedule VI, Para IV of the Companies Act, 1956)

i.	REGISTRATION DETAILS Registration No L7489DL19 State Code Balance Sheet Date	85PLC022468 55 31/03/2011
11.	CAPITAL RAISED DURING THE YEAR (AMOUNT IN RS. THOUSAND) Public Issue Bonus Issue Right Issue Private Placement	Nil Nil Nil Nil
III.	POSITION OF MOBILISATION AND DEPLOYMENT OF FUNDS Total Liabilities Total Assets SOURCES OF FUNDS Paid up Capital Reserve & Surplus Secured Loans Unsecured Loans APPLICATION OF FUNDS Net Fixed Assets Investments Net Current Assets Misc. Expenditure Accumulated Losses	54198.5 54198.5 30,003 21195.5 Nil Nil 300 41650.71 Nil 9604.16
IV.	PERFORMANCE OF COMPANY (AMOUNT IN RS. THOUSANDS) Turnover Total Expenditure Profit/(Loss) Before Tax Profit/Loss After Tax Earning Per Shares (in Rs.) Dividend rate	161304.52 157183.53 4121.00 2134.54 1.16 0
V.	GENERAL NAMES OF THREE PRINCIPAL PRODUCTS/SERVICES OF COMPANY (AS PEI MONETARY TERMS) Item Code No. (ITC Code) Product Description: Item Code No. (ITC Code) Product Description:	R N.A.
	For and on behalf of the Board of Directo	ors
	Place: New Delhi	

Sd/-Amit Bansal (Company Secretary) Sd/-

Brij Bala Gupta

(Director)

(Chairman-cum-Managing Director)

Sd/-

B R Gupta

Brawn Biotech Limited

(Formerly Brawn Pharmaceuticals Limited)
Regd. Office: C-64, Lajpat Nagar-I, New Delhi - 110024

Folio No.	ATTENDANCE SLIP	Client ID No	
<u>.</u>		DPID No.	
Name:			
	· · · · · · · · · · · · · · · · · · ·		
I hereby record my pre	sence at the 26th Annual General Meeting of to 04.00 p.m. at "The Executive Club", 439	the Company held	on Friday the
SIGNATUREOFTHEAT	TENDINGMEMBER/PROXY*		
and hand ove	roxyholder wishing to attend the meeting must br or the same at the entrance duly signed.	ring the Attendance	Slip to the mee
	icheveris not applicable.		
** Applicable to	r investors holding shares in electronic form.		
	NR · No Gift Coupon will be distributed:	at the AGM	
	NB.: No Gift Coupon will be distributed	at the AGM	
	NB.: No Gift Coupon will be distributed a	at the AGM	
	NB.: No Gift Coupon will be distributed a	at the AGM	
	Brawn Biotech Lir	mited	
		mited	
	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, Nev	mited als Limited) w Delhi - 110024	
Folio No.	Brawn Biotech Lir	mited als Limited) W Delhi - 110024	
Folio No.	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, Nev	mited als Limited) w Delhi - 110024	
	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, Nev	mited als Limited) W Delhi - 110024	
I/weof	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, New PROXY FORM	mited als Limited) w Delhi - 110024 ** Client ID No DPID No. member/members	
I/weof	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, New PROXYFORM being a reaction	mited Is Limited) W Delhi - 110024 Client ID No DPID No.	of the above na
I/weof	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, New PROXY FORM being a root	mited als Limited) W Delhi - 110024 Client ID No DPID No.	of the above na _of failing him/h
I/weof Company, herebyappoir	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, New PROXYFORM being a read to the control of	mited als Limited) w Delhi - 110024 ** Client ID No DPID No. member/ members	of the above na _of failing him/h
I/weof Company, herebyappoir	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, New PROXY FORM being a root	mited als Limited) w Delhi - 110024 ** Client ID No DPID No. member/ members	of the above na _of failing him/h
I/weof Company, herebyappoir on my/our behalf at the 2 2011 at 04.00 p.m. or at a	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, New PROXY FORM being a restriction of	rited Is Limited) V Delhi - 110024 Client ID No DPID No. member/ members proxy to attend and eheld on Friday, the	of the above na _of failing him/h
I/weof Company, herebyappoir on my/our behalf at the 2 2011 at 04.00 pm. or at a Signed this	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, New PROXY FORM being a real of	mited als Limited) w Delhi - 110024 ** Client ID No DPID No. member/ members proxy to attend and e held on Friday, the	of the above na _of failing him/h d vote for me/us a 30th Septembe
I/weof Company, herebyappoir on my/our behalf at the 2 2011 at 04.00 pm. or at a Signed this	Brawn Biotech Lir (Formerly Brawn Pharmaceutica Regd. Office: C-64, Lajpat Nagar-I, New PROXY FORM being a real as my/our 6th Annual General Meeting of the Company to be	mited als Limited) w Delhi - 110024 ** Client ID No DPID No. member/ members proxy to attend and e held on Friday, the	of the above na _of failing him/h d vote for me/us

Brawn Biotech LimitedOld Delhi Stock Exchange Building
4/4B, Asaf Ali Road,
New Delhi - 110 002